PSMA-Targeting Radioligand Therapy in Prostate Cancer

Michael Wissmeyer[1a], Magdalena Kulgawczuk[1]

[1] Institute of Radiology und Nuclear Medicine, Stadtspital Zurich, Switzerland

healthbook TIMES Oncology Hematology

Radioligand therapy targeting prostate-specific membrane antigen (PSMA) represents a significant advancement in the treatment of metastatic prostate cancer. This theranostic approach involves the use of diagnostic radiotracers that specifically bind to PSMA, such as ^{68}Ga-PSMA-11, to identify PSMA-positive disease. Therapeutically, radioligands such as ^{177}Lutetium-PSMA-617 have shown promise for delivering targeted radiation to PSMA-expressing tumor cells. This review summarizes recent findings from key clinical trials, focusing on the state-of-the-art in radioligand therapy and optimal patient selection, as well as dosing of radionuclide therapy in special situations, including diffuse bone marrow involvement and renal toxicity.

PEER REVIEWED ARTICLE

Peer reviewers:

PD Dr Aurelius Omlin, Onkozentrum Zurich, Zurich, Switzerland

Dr Ole Maas, HOCH Health Ostschweiz, St. Gallen, Switzerland

Dr Marco Cuzzocrea, Cantonal Hospital Bellinzona (EOC), Bellinzona, Switzerland

Introduction

Prostate cancer is the second most prevalent malignancy and the fifth leading cause of death among men globally.[1] The disease progresses through multiple stages, starting with localized, organ-confined cancer and advancing to metastatic phases, which are classified by hormonal responsiveness. In localized, early-stage prostate cancer, the prognosis is generally favorable, with a 10-year overall survival (OS) rate of 98%.[1,2] Treatment options for

a Corresponding author:
PD Dr Michael Wissmeyer
Chefarzt
Institut für Radiologie und Nuklearmedizin
Stadtspital Zurich Waid
Tièchestrasse 99
8037 Zurich
Switzerland
Email: michaelpeter.wissmeyer@stadtspital.ch

localized prostate cancer include active surveillance, ablative radiotherapy and radical prostatectomy.[3] However, the prognosis worsens dramatically when the disease progresses to metastatic stages, characterized by tumor cell dissemination mostly to the bone and lymph nodes, resulting in a 5-year OS rate of only 30%.[1,4]

As androgen receptor signaling is crucial for tumor growth and survival in the metastatic stage, androgen deprivation therapy (ADT) has been the standard of care (SoC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).[3,5] Combining ADT with androgen receptor pathway inhibitors (ARPIs) has further improved patient outcomes. In mHSPC, chemotherapy and the combination of ARPI with chemotherapy also significantly prolong OS. Although most patients initially respond to ADT, many will eventually develop castration resistance, which leads to androgen-independent tumor growth and signifies a transition to the more aggressive, incurable state of metastatic castration-resistant prostate cancer (mCRPC), associated with a poor prognosis and a mean survival of only 16–18 months.[6,7] In recent years, several classes of novel drugs have been introduced into clinical practice, including ARPIs, taxanes, poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapies, which have demonstrated significant survival benefits for these patients.[3,8-11]

Recent advancements in prostate cancer treatment include the development of therapies targeting prostate-specific membrane antigen (PSMA). PSMA is a type II transmembrane glycoprotein encoded by the folate hydrolase 1 (FOLH1) gene,[12] which is present on the benign prostate epithelium and other tissues. Its expression is markedly upregulated in prostate adenocarcinoma cells, including metastatic lesions in mCRPC patients, correlating with poor prognosis.[13-16]

As a transmembrane protein with a known substrate, PSMA is overexpressed on prostate cancer cells and internalizes upon ligand binding, making it an attractive target for small-molecule ligands designed for both diagnostic and therapeutic purposes. This combined approach, known as theranostics, utilizes radiotracers that selectively bind to PSMA, such as ^{68}Ga-PSMA-11, for positron emission tomography (PET) imaging of PSMA-positive disease.[17] Therapeutically, radioligands, such as [177]Lutetium (Lu)-PSMA-617 (^{177}Lu-PSMA-617), have shown potential as a radionuclide therapy option for targeted delivery of β-radiation to PSMA-expressing tumor cells, causing DNA damage and cytotoxicity.[18,19] This dual approach thus enables visualization and selective treatment of prostate cancer at advanced stages.

Figure 1. Radiographic progression-free survival in the VISION trial.

^{177}Lu-PSMA-617, [177]Lutetium-prostate-specific membrane antigen-617. Adapted from Sartor et al. 2021.[20]

PSMA radioligand therapy: The state of the art

The VISION trial: ^{177}Lu-PSMA-617 improves rPFS and OS in patients with mCRPC

The registrational, open-label VISION trial investigated ^{177}Lu-PSMA-617 in 831 patients with mCRPC who had previously received at least one ARPI and one to two taxane regimens and had PSMA-positive ^{68}Ga-PSMA-11 PET/computed tomography (CT) scans.[20] At a median follow-up of 20.9 months, patients treated with ^{177}Lu-PSMA-617 plus SoC versus SoC alone achieved significantly improved radiographic progression-free survival (rPFS) (median: 8.7 months vs 3.4 months; HR: 0.40 [99.2% CI: 0.29–0.57]; p<0.001) (**Figure 1**) and OS (median: 15.3 months vs 11.3 months; HR: 0.62 [95% CI: 0.52–0.74]; p<0.001).

In terms of safety, treatment with ^{177}Lu-PSMA-617 was generally manageable.[20] Hematologic grade ≥3 adverse events (AEs) were more frequent with ^{177}Lu-PSMA-617 plus SoC than SoC alone and most commonly included anemia (12.9% vs 4.9%), thrombocytopenia (7.9% vs 1.0%) and lymphopenia (7.8% vs 0.5%). Further analyses of the VISION study showed that ^{177}Lu-PSMA-617 plus SoC delayed the time to worsening of health-related quality of life (HRQoL) compared with SoC alone.[21] In particular, ^{177}Lu-PSMA-617-containing treatment was associated with prolonged time to worsening of the FACT-P score (HR: 0.54), BPI-SF pain intensity score (HR: 0.52) and EQ-5D-5L utility score (HR: 0.65). ^{177}Lu-PSMA-617 also prolonged the time to first skeletal event or death (median: 11.5 months vs 6.8 months with SoC alone; HR: 0.50).

The recent VISION dosimetry sub-study, which quantified absorbed doses of ^{177}Lu-PSMA-617 in the kidneys and other organs, showed that ^{177}Lu-PSMA-617 had a good safety profile with low radiotoxicity in organs at risk.[22] A further analysis of tumor dosimetry for ^{177}Lu-PSMA-617 across cycles 1–6 was conducted in a cohort of 29 non-randomized patients who received up to six cycles of ^{177}Lu-PSMA-617 (7.4 GBq every six weeks) plus SoC.[23] Patients underwent single-photon emission computed tomography (SPECT)/CT scans to assess tumor uptake and calculate radiation-absorbed doses over time. Data from 60 delineated prostate cancer lesions were analyzed across cycles 1–6 in 18 patients who had evaluable tumors in cycles 2–6. The mean absorbed dose across all tumors decreased from 7.9 Gy/GBq in cycle 1 to 1.6 Gy/GBq by cycle 6, indicating reduced radiation delivery to tumors over successive cycles. Mean absorbed doses decreased from 6.4 Gy/GBq in cycle 1 to 1.3 Gy/GBq in cycle 6 for bone tumors and from 11 Gy/GBq in cycle 1 to 3.2 Gy/GBq in cycle 6 for lymphatic metastases. Patients received a median cumulative absorbed dose of approximately 100 Gy over six cycles. The declining absorbed doses across cycles 1–6 in this dosimetry sub-study align with the demonstrated anti-tumor efficacy of ^{177}Lu-PSMA-617 observed in the VISION trial.

TheraP: ^{177}Lu-PSMA-617 yields higher PSA50 rates versus cabazitaxel

Another trial assessing the efficacy of ^{177}Lu-PSMA-617 against cabazitaxel in patients with mCRPC for whom cabazitaxel was considered the next appropriate standard treatment was the randomized phase II TheraP trial, which included 200 patients.[24] The study met its primary endpoint of prostate-specific antigen (PSA) response, defined as a reduction of at least 50% from baseline (PSA50), with significantly higher PSA50 rates under ^{177}Lu-PSMA-617 compared with cabazitaxel (66% vs 37% by intention-to-treat; p<0.0001). A pre-specified sensitivity analysis by treatment received showed a PSA50 response in 66% of men treated with ^{177}Lu-PSMA-617 versus 44% of those treated with cabazitaxel (p=0.0016).

Treatment with ^{177}Lu-PSMA-617 also delayed disease progression compared with cabazitaxel in terms of both rPFS (HR: 0.64 [95% CI: 0.46–0.88]; p=0.0070) and PSA PFS (HR: 0.60 [HR: 0.44–0.83]; p=0.0017). At a median follow-up of 36 months, OS analysis by intention-to-treat, summarized as restricted mean survival time (RMST), demonstrated similar OS between patients receiving ^{177}Lu-PSMA-617 and cabazitaxel (RMST, 19.1 months vs 19.6 months; p=0.77).[25] In a safety analysis (n=183), grade 3–4 AEs occurred in 33% of men in the ^{177}Lu-PSMA-617 group and 53% in the cabazitaxel group.

Based on the results from the VISION and TheraP studies, both the European Association of Urology (EAU) and the American Society of Clinical Oncology (ASCO) recommend ^{177}Lu-PSMA-617 for patients with pretreated mCRPC who show high PSMA expression (exceeding the uptake in the liver) on the diagnostic radiolabeled PSMA PET/CT scan.[26,27]

PSMAfore: Moving to earlier lines of therapy

More recent research has demonstrated that ^{177}Lu-PSMA-617 is also an effective treatment option for mCRPC in earlier lines of therapy. The randomized, open-label, phase III PSMAfore study evaluated the efficacy of ^{177}Lu-PSMA-617 in taxane-naïve patients with mCRPC who had progressed once after a prior ARPI.[28] In this study, 468 patients underwent 1:1 randomization to receive either ^{177}Lu-PSMA-617 at a dosage of 7.4 GBq once every six weeks for six cycles or a change of ARPI (abiraterone or enzalutamide).

In the primary analysis, with a median follow-up of 7.26 months, the median rPFS was 9.30 months in the ^{177}Lu-PSMA-617 group compared with 5.55 months in the ARPI change group (HR: 0.41 [95% CI: 0.29–0.56]; p<0.0001).[28] An updated analysis at a median follow-up of 24.11 months confirmed this benefit, showing a median rPFS of 11.60 months for the ^{177}Lu-PSMA-617 group versus 5.59 months for the ARPI change group (HR: 0.49 [95% CI: 0.39–0.61]) (**Figure 2**). Regarding safety, the incidence of grade 3–5 AEs was lower with ^{177}Lu-PSMA-617, with at least one event occurring in 36% of patients, including four grade 5 events (none of them treatment-related). In comparison, 48% of patients receiving ARPI change had grade 3–5 AEs, including five (2%) grade 5 events (one of them treatment-related).

UpFrontPSMA: ^{177}Lu-PSMA-617 as a treatment option for mHSPC

Ample evidence shows that ^{177}Lu-PSMA-617 improves survival and QoL in patients with mCRPC, but its benefit in hormone-sensitive disease has only been investigated recently. In this context, the phase II UpFrontPSMA study aimed to evaluate the impact of ^{177}Lu-PSMA-617 prior to the introduction of docetaxel treatment in adult patients with *de novo* high-volume metastatic hormone-sensitive prostate cancer (mHSPC).[29] In total, 130 patients were randomly assigned in a 1:1 manner to receive either ^{177}Lu-PSMA-617 (two cycles of ^{177}Lu-PSMA-617 at 7.5 GBq every six weeks) followed by docetaxel six weeks later (every three weeks) versus SoC and docetaxel alone (six cycles every three weeks). All patients received continuous ADT.

The primary endpoint of undetectable PSA (≤0.2 ng/mL) at 48 weeks was achieved in 41% of patients in the ^{177}Lu-PSMA-617 plus docetaxel group compared with 16% of patients in the docetaxel alone group (OR: 3.88 [95%

Figure 2. Radiographic progression-free survival in the PSMAfore trial.

^{177}Lu-PSMA-617, [177]Lutetium-prostate-specific membrane antigen-617; ARPI, androgen receptor pathway inhibitor. Adapted from Morris et al. 2024.[28]

CI: 1.61–9.38]; p=0.0020).[29] Additionally, undetectable PSA at any time was observed in 51% of patients receiving the combination therapy versus 32% of those receiving docetaxel alone (OR: 2.14 [95% CI: 1.03–4.46]; p=0.042). The median PSA PFS was 31 months in the combination group versus 20 months in the docetaxel alone group (HR: 0.60 [95% CI: 0.37–0.98]; p=0.039) and the median rPFS was not reached versus 22 months, respectively (HR: 0.58 [95% CI: 0.32–1.05]; p=0.067). The median OS was not reached in either arm (HR: 0.83 [95% CI: 0.38–1.83]; p=0.646). In terms of safety, the most common grade 3 or 4 treatment-related AEs were febrile neutropenia (11% with combination therapy vs 10% with docetaxel alone) and diarrhea (6% vs 0%). Serious adverse events occurred in 25% of patients in each treatment arm.

ENZA-p: Adding enzalutamide to ^{177}Lu-PSMA-617 improves clinical outcomes

Enzalutamide and ^{177}Lu-PSMA-617 both improve OS in patients with mCRPC,[20,30,31] and targeting both androgen and PSMA receptors simultaneously might provide complementary benefits due to their close intracellular relationship. The combination of enzalutamide and ^{177}Lu-PSMA-617 was therefore assessed as the first-line treatment for high-risk mCRPC in the phase II ENZA-p trial.[32] In this study, 162 patients were

randomized to receive either enzalutamide (160 mg daily) plus dose-adapted ^{177}Lu-PSMA-617 (two or four doses; 7.5 GBq ^{177}Lu-PSMA-617 every 6–8 weeks) or enzalutamide alone.

At a median follow-up of 20 months, the median PSA PFS was 13.0 months in the combination arm (n=83) and 7.8 months in the enzalutamide-alone arm (n=79) (HR: 0.43 [95% CI: 0.29–0.63]; p<0.0001).[32] The PSA90 reduction rate was also considerably higher with enzalutamide plus ^{177}Lu-PSMA-617, with 78% of patients achieving a 90% reduction in PSA levels compared with 37% with enzalutamide alone. The recently reported secondary endpoint of OS favored the combination treatment, with a median of 34 months versus 26 months for enzalutamide alone (HR: 0.55 [95% CI: 0.36–0.84]; p=0.0053).[33]

Among 162 patients with available HRQoL data, enzalutamide plus ^{177}Lu-PSMA-617 significantly improved deterioration-free survival at 12 months compared with enzalutamide alone for both physical function (median, 10.64 months vs 3.42 months; HR: 0.51 [95% CI: 0.36–0.72]; p<0.0001) and overall health and QoL (median, 8.71 months vs 3.32 months; HR: 0.47 [95% CI: 0.33–0.67]; p=0.0001).[33] Additionally, pain and fatigue scores favored the combination treatment (pain difference: 7.3; p=0.012, fatigue difference: 5.9; p=0.016).

Safety analysis showed that grade 3–5 AEs occurred in 40% of patients in the enzalutamide plus ^{177}Lu-PSMA-617 group and 41% of patients in the enzalutamide group.[32] Grade 3 AEs that occurred only in the combination group included anemia (4%) and decreased platelet count (1%).

SPLASH: ^{177}Lu-PNT2002 prolongs rPFS in mCRPC patients

^{177}Lu-PNT2002 (^{177}Lu-PSMA-I&T) is another Lu-PSMA-containing radio-conjugate that has demonstrated significant clinical activity in patients with mCRPC following ARPI therapy. In the phase III SPLASH trial, 412 patients were randomly assigned in a 2:1 ratio to receive either ^{177}Lu-PNT2002 at 6.8 GBq once every eight weeks for up to four cycles or an alternate ARPI (enzalutamide or abiraterone acetate).[34]

The study met its primary endpoint, showing a median rPFS of 9.5 months in the ^{177}Lu-PNT2002 arm compared with 6.0 months in the ARPI arm, at a median follow-up of 11.1 months and 12.9 months, respectively (**Figure 3**).[34] This corresponded to a significant 29%-reduction in the risk of progression or death (HR: 0.71 [95% CI: 0.55–0.92]; p=0.0088). Treatment with ^{177}Lu-PNT2002 also led to a significantly improved best overall response rate (ORR) at 38.1% in the ^{177}Lu-PNT2002 arm and 12% in the ARPI arm (p=0.0021), with a median duration of response of 9.4 months versus 7.3 months, respectively. The complete response (CR) rate was 9.3%

Figure 3. SPLASH: The primary endpoint of radiographic progression-free survival was significantly improved in patients receiving ^{177}Lu-PNT2002 versus alternate androgen receptor inhibitor (ARPI).

Abi, abiraterone acetate; Enza, enzalutamide. Adapted from Sartor et al. 2024.[34]

with ^{177}Lu-PNT2002, while no CRs were observed with ARPI. In the ^{177}Lu-PNT2002 arm, 35.7% of evaluable patients achieved at least a 50% PSA decrease from baseline, compared with 14.6% in the ARPI arm.

^{177}Lu-PNT2002 also demonstrated a favorable safety profile.[34] Grade ≥3 treatment-emergent AEs occurred in 30.1% of patients in the ^{177}Lu-PNT2002 arm and 36.9% in the ARPI arm, with treatment-related grade ≥3 treatment-emergent AEs (TEAEs) of 9.7% and 11.5%, respectively. Serious TEAEs were reported in 23.1% of patients in the ^{177}Lu-PNT2002 arm versus 17.1% in the ARPI arm, with treatment-related serious TEAEs occurring in 2.2% of ^{177}Lu-PNT2002 patients compared with 3.8% of ARPI patients. The full publication of the SPLASH trial is still awaited.

While the SPLASH trial shares many similarities with the PSMAfore trial, as both compare PSMA-targeted therapy with ARPI treatment, key differences exist. Both studies confirm the superiority of PSMA-targeted radioligand therapy over ARPI treatment in mCRPC patients, but differences in dosing, treatment cycles and clinical outcomes provide important insights.[28,34] SPLASH evaluated ^{177}Lu-PNT2002 at 6.8 GBq every eight weeks for four cycles, demonstrating a median rPFS of 9.5 months versus 6.0 months with ARPI (HR: 0.71).[34] In contrast, PSMAfore investigated ^{177}Lu-PSMA-617 at 7.4 GBq every six weeks for six cycles, which led to a slightly longer median rPFS of 11.6 months in the updated analysis compared with 5.59 months with ARPI (HR: 0.49).[28] Safety profiles also varied slightly, with grade ≥3 TEAEs occurring in 30.1% of SPLASH patients versus 36% in PSMAfore, although ARPI arms in both trials had higher toxicity rates.[28]

SatisfACtion: an ongoing study of ^{225}Ac-PSMA-R2

Newly developed compounds emitting α particles, such as Actinium-225 (^{225}Ac), are showing promise due to their potential to cause more significant DNA damage in tumor cells by a significantly increased number of double-strand breaks compared to β-emitters.[35] Actinium-225 conjugated to radio-labeled PSMA-R2 (^{225}Ac-PSMA-R2) is currently under investigation in the SatisfACtion study in patients with PSMA-positive mCRPC who have previously undergone ARPI and taxane therapy.[36] In this phase I/II study, patients receive intravenous ^{225}Ac-PSMA-R2 plus SoC once every six weeks for up to six cycles. The dose-escalation phase evaluates the safety, tolerability and recommended dose for expansion of ^{225}Ac-PSMA-R2. Dose escalation is performed in each group using independent Bayesian logistic regression models following the escalation with the overdose control (EWOC) principle. The initial dose of 7 MBq may be increased to 10, 12 or 14 MBq if the EWOC criteria are met and safety profiles remain acceptable. Primary endpoints in the dose-escalation phase include the incidence and severity of dose-limiting toxicities, AEs and serious AEs, dose intensity and treatment modifications. In the dose-expansion phase, the primary endpoints are ORR and PSA50 response rate. Secondary endpoints in both phases include response rates, rPFS, PFS, OS, the time to symptomatic skeletal event, among others.

Patient selection for radioligand therapy

^{177}Lu-PSMA-617 is an effective treatment providing longer survival with improved QoL in patients with mCRPC who have previously received ARPI and taxane therapy. However, as shown above, patient response to ^{177}Lu-PSMA-617 treatment varies and it is therefore crucial to identify those who most likely benefit from such a treatment. The VISION and TheraP trials used different criteria for patient selection based on PSMA-PET.[37,38]

In the VISION trial, patients had to have PSMA-positive disease based on ^{68}Ga-PSMA-11 staging PET/CT scans, defined as a greater uptake in metastatic lesions than in the liver, and the absence of PSMA-negative metastatic lesions.[39] Using these criteria, 13% of the screened men were deemed trial-ineligible, while 46% of the remaining and treated patients achieved a PSA50 response with radioligand therapy. Conversely, the TheraP trial required high PSMA expression with at least one site with a standardized uptake value $(SUV)_{max}$ >20, which was approximately 4–5 times higher than that required for patients in the VISION trial, and no sites of ^{18}F-fluorodeoxyglucose (FDG)-positive/PSMA-negative disease.[24] Due to these more stringent criteria, 31% of screened patients were ineligible, while 65% of the treated patients achieved a PSA50 response. These data highlight that the correct application of imaging parameters can significantly influence the treatment choice and response rates to radionuclide therapy.

Figure 4. Prognostic value of standardized uptake value (SUV)$_{mean}$ >10 in TheraP.

PSA50, ≥50% decrease in PSA levels; PSMA-RLT, prostate-specific membrane antigen radioligand therapy. Adapted from Buteau et al. 2022.[37]

As PSMA-PET has emerged as a reference imaging tool for the staging and restaging of patients with prostate cancer for both clinical routine and trials, the recently developed PROMISE V2 criteria have been proposed as a set of guidelines designed to standardize the assessment of prostate cancer using updated molecular imaging TNM staging, improved assessment of local disease and a slightly modified PSMA-expression score for clinical routine.[40] Key points include standardized imaging protocols, lesion characterization based on specific imaging features and a structured reporting system to facilitate communication among healthcare professionals.

Ad hoc analyses of both VISION and TheraP demonstrated that a high SUV at baseline is associated with superior event-free survival (EFS) and OS.[37,38] In VISION, patients in the top quartile (SUV$_{mean}$ ≥9.9) experienced the greatest benefit from treatment, while those with SUV$_{mean}$ <9.9 showed no substantial difference in response rates. In TheraP, patients with SUV$_{mean}$ ≥10 achieved higher PSA50 response rates and PSA PFS compared with those with SUV$_{mean}$ <10 (response rates, 91% vs 52%; HR: 0.45 vs 0.77) (**Figure 4**). Notably, SUV$_{mean}$ ≥10 was predictive of favorable general response in patients, regardless of the receipt of cabazitaxel or PSMA radioligand therapy in the TheraP trial.

Both the VISION and TheraP trials reported that 22% of patients had SUV$_{mean}$ >10.[37,38] However, the "gap" between these two trials, accounting for approximately 17% of patients who failed screening in TheraP but passed in VISION, raises questions about selection criteria. Analysis of this cohort showed that 39% of patients achieved a PSA50 response,[41] suggesting that patients with an SUV$_{mean}$ ≤10 should not necessarily be excluded from radioligand therapy.

The role of FDG-PET in patient selection was investigated in an *ad hoc* analysis of TheraP, which showed its predictive value, with screen failure indicating significantly worse responses.[37] However, FDG-PET is not recommended for routine use across all patients, as it may only identify a small number beyond what PSMA-PET alone would detect. Patients should be selected for PSMA radioligand therapy based on an uptake greater than that in the liver. While showing prognostic value, SUV$_{mean}$ >10 is not relevant for clinical decision-making in the current patient population, although it may be more relevant earlier in the disease course. Furthermore, nomograms have proven unreliable for identifying patients who respond to

PSMA radioligand therapy and are therefore not recommended for clinical use. Post-chemotherapy, patients should be given the opportunity to undergo radioligand therapy whenever feasible.

Further multivariable models have been developed of OS, rPFS and PSA50 response after treatment with ^{177}Lu-PSMA-617, using data from the VISION trial.[42] In single pretreatment parameter analyses, 22 parameters (76%) were associated with OS, 21 (72%) with rPFS and 10 (34%) with PSA50 in the overall VISION population. More specifically, the OS nomogram included SUV_{max}, time since diagnosis, opioid analgesic use, aspartate aminotransferase (AST), hemoglobin, lymphocyte count, presence of PSMA-positive lesions in lymph nodes, lactate dehydrogenase (LDH), alkaline phosphatase (ALP) and neutrophil count. The rPFS nomogram included SUV_{max}, time since diagnosis, opioid analgesic use, lymphocyte count, presence of liver metastases by computed tomography, LDH and ALP, while for PSA50, included factors were SUV_{max}, lymphocyte count and ALP. Higher levels of ALP, AST and LDH, along with the presence of liver metastases, were associated with poorer OS, rPFS and PSA50 outcomes. Conversely, higher hemoglobin levels, neutrophil counts, SUV_{mean} and SUV_{max}, and longer time since prostate cancer diagnosis correlated with improved OS, rPFS and PSA50. Notably, higher SUV_{max} or SUV_{mean} was associated with higher PSA50 response rates in the ^{177}Lu-PSMA-617 plus SoC group, although no specific parameters significantly predicted improved OS or rPFS in this treatment arm versus the SoC arm. In multivariable modeling, Spearman's rank correlation analysis identified co-linearity in three pairs of parameters: neutrophil-to-lymphocyte ratio (NLR) with pan-immune-inflammation value; neutrophil count with white blood cell count; and SUV_{mean} with SUV_{max}. These models show that a combination of pretreatment laboratory, clinical and imaging parameters, reflecting both patient and tumor status, influences the outcomes.

Repeated imaging with post-treatment SPECT can effectively evaluate PSMA uptake in patients undergoing ^{177}Lu-PSMA-617 therapy.[43] Patient response evaluated by PSA levels, imaging data and other factors, such as patient symptoms and toxicities, can be used to guide decisions on delaying or discontinuing treatment. Since the radionuclide ^{177}Lu emits gamma photons, SPECT imaging can track patients over time without the need for further PSMA-PET, helping to monitor response and adjust therapy. As shown in the RE-SPECT study, patients who showed a response may benefit from treatment delays, sparing additional therapy in early responders, decreasing toxicity and potentially extending OS (**Figure 5**).[44] For those with heterogeneous responses, post-treatment scans can be used to determine disease progression before stopping treatment. In fact, one study demonstrated that post-treatment SPECT led to changes in disease management in 49% of patients, suggesting that it may be a more effective

	PSA 50% RR	Median PSA Response	OS	PSA-PFS
Overall	60% (75/125)	51.8% (86.2 to -1.6)	16.8 (13.5–20.1)	6.1 (5.4–6.7)
RG 1	93% (38/41)	83% (-97 to -70)	19.2 (16.8–20.7)	12.1 (9.3–17.4)
RG 2	74% (29/39)	61% (89 to -35)	13.2 (12.0–18.8)	6.1 (5.8–9.0)
RG 3	8% (3/36)	-25% (-55 to -1)	11.2 (8.7–15.6)	2.6 (1.6–3.1)

Figure 5. RE-SPECT: Early response biomarkers, such as ^{177}Lu-PSMA-617, can be used for personalized therapy.

OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; PSA, prostate-specific antigen; PSA50, ≥50% decrease in PSA levels; RG, response group; RR, response rate; SD, stable disease; SPECT, single-photon emission computed tomography. Adapted from Emmett et al. 2023.[44]

approach than PSMA-PET for managing immediate post-treatment responses.[45] However, SPECT imaging in clinical routine remains qualitative, while PET imaging provides quantitative imaging data for patient- and lesion-level response assessment, as well as quantitative prognostic data. Conventional imaging techniques, such as CT and magnetic resonance imaging (MRI), are still required to detect the development of PSMA-negative disease.

Use of radioligand therapy in special conditions

In the VISION trial, which included patients with compromised bone marrow function, the exposure-adjusted incidence of TEAEs per 100 patients-treatment years was generally similar in patients receiving ^{177}Lu-PSMA-617 and those receiving SoC.[46] Hematologic grade ≥3 TEAEs included anemia (16.7% with ^{177}Lu-PSMA-617 vs 14.0% with SoC) and thrombocytopenia (10.0% vs 2.8%); neutropenia and acute kidney injury were uncommon (4.3% vs 1.4% and 3.8% vs 6.9%). Additionally, a multicenter retrospective study evaluating the efficacy and safety of ^{177}Lu-PSMA-617 in 390 patients, 43 of whom had diffuse bone marrow involvement, reported a PSA50 response rate of 58%, with rates of grade 3 hematologic AEs similar to those observed in VISION (anemia, 22%; thrombocytopenia, 17%).[47] These data suggest that patients with bone marrow involvement can generally be safely treated with radioligand therapy.

Figure 6. Tumor heterogeneity predicts poor response to 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC).

Adapted from Swiha et al. 2024[49] and Emmett L. 2023.[50]

In managing bone marrow toxicity associated with ^{177}Lu-PSMA-617 therapy, it is important to distinguish between pre-existing and treatment-related bone marrow compromise. In patients with high-volume disease, higher doses of radioactivity may be required to ensure a suitable environment for future bone marrow cell growth. This is because standard doses (7.4 GBq of ^{177}Lu-PSMA-617) may not achieve sufficient therapeutic concentrations in high-volume disease due to a dilution effect. A phase I/II study demonstrated that dose fractionation up to a maximum of 22.0 GBq led to higher cumulative radiation doses, a decreased frequency and depth of PSA response, as well as increased OS and toxicity with higher treatment activities.[48]

Tumor heterogeneity also impacts response to radioligand therapy and should therefore be considered during patient selection. A novel visually calculated score incorporating heterogeneity and intensity of tumors classified mCRPC patients into four categories based on SUV_{max} and tumor intensity: (1) SUV_{max} <15, (2) SUV_{max} 15–79 with heterogeneous intensity, (3) SUV_{max} 15–79 with homogenous intensity and (4) SUV_{max} ≥80.[49] Data from different studies demonstrated that a higher heterogeneity index is associated with poor response to ^{177}Lu-PSMA-617 (**Figure 6**). Patients with highly heterogeneous tumors may experience grade 1–2 anemia and disease progression after treatment, which increase their risk of bone marrow impairment.

Renal toxicity data for ^{177}Lu-PSMA-617 are limited, particularly from prospective studies. A retrospective analysis of 106 patients receiving a minimum of four doses of ^{177}Lu-PSMA-617 reported that the estimated glomerular filtration rate (eGFR) decreased progressively, reaching a 19.6% reduction at 24 months.[51] The risk factors associated with impaired eGFR included hypertension, diabetes, older age and prior taxane chemotherapy. In patients with pre-treatment chronic kidney failure, ^{177}Lu-PSMA-617 therapy did not lead to a detectable deterioration in renal function, suggesting that such patients should not be categorically excluded from radionuclide therapy.[52] Despite these findings, there are still many gaps in our knowledge of delayed renal toxicity associated with ^{177}Lu-PSMA-617, but ongoing trials are expected to provide further insights into the long-term renal safety profile of ^{177}Lu-PSMA-617 therapy.

As ^{177}Lu-PSMA-617 therapy moves into the early stage of disease, adaptive dosing is emerging as an important tool for delaying or reducing the radiation dose in patients who do not benefit from the treatment, thus reducing long-term toxicity. This approach was utilized in the ENZA-p trial where patients received adaptive-dosed ^{177}Lu-PSMA-617 every 6–8 weeks depending on an interim PSMA-PET/CT.[32]

Conclusions

- Radionuclide-based theranostics is ready for widespread adoption in prostate cancer therapy, including in early treatment lines.

- PSMA radioligand therapy should be reserved for patients with lesions that demonstrate greater PSMA uptake than that observed in the liver. The use of PSMA-SUV$_{mean}$ and nomograms is not recommended for determining the eligibility for PSMA radioligand therapy and FDG-PET should be reserved for specific cases.

- The newly developed PROMISE V2 criteria may be a valuable guide to optimal patient selection in the radioligand treatment of prostate cancer.

- Post-treatment SPECT can be used to monitor patient responses over time and adjust the treatment in a personalized manner.

- While grade 1–2 marrow toxicity is common with PSMA-targeted radionuclide therapy, composite biomarkers will help identify the cause of marrow compromise and guide future treatments.

- Renal toxicity requires further evaluation in clinical trials, with long-term toxicity becoming more relevant as the treatment moves towards earlier stages in patients with longer life expectancy.

....

Conflict of interest

The authors have declared that the manuscript was written in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding

The authors have declared that no financial support was received from any organization for the submitted work.

Author contributions

The authors created and approved the final manuscript.

REFERENCES

1. Cancer Stat Facts: Prostate Cancer. National Cancer Instutute. Accessed February 2025. https://seer.cancer.gov/statfacts/html/prost.html

2. Herr DJ, Elliott DA, Duchesne G, et al. Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system. *Cancer*. 2023;129(20):3326-3333. doi:10.1002/cncr.34916

3. Fizazi K, Gillessen S. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. *Ann Oncol*. 2023;34(6):557-563. doi:10.1016/j.annonc.2023.02.015

4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin*. 2018;68(1):7-30. doi:10.3322/caac.21442

5. Ong S, O'Brien J, Medhurst E, et al. Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer-a narrative review. *Transl Androl Urol*. 2021;10(10):3918-3930. doi:10.21037/tau-20-1118

6. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. *Oncogene*. 2013;32(49):5501-5511. doi:10.1038/onc.2013.206

7. Cai M, Song XL, Li XA, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. *Drug Resist Updat*. 2023;68:100962. doi:10.1016/j.drup.2023.100962

8. Mitsiades N, Kaochar S. Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer. *Endocr Relat Cancer*. 2021;28(8):T19-T38. doi:10.1530/erc-21-0098

9. Sandhu S, Moore CM, Chiong E, et al. Prostate cancer. *Lancet*. 2021;398(10305):1075-1090. doi:10.1016/s0140-6736(21)00950-8

10. Tisseverasinghe S, Bahoric B, Anidjar M, Probst S, Niazi T. Advances in PARP Inhibitors for Prostate Cancer. *Cancers (Basel)*. 2023;15(6):1849. doi:10.3390/cancers15061849

11. Wang I, Song L, Wang BY, et al. Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy. *Am J Clin Exp Urol*. 2022;10(4):210-233.

12. Rinker-Schaeffer CW, Hawkins AL, Su SL, et al. Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11. *Genomics*. 1995;30(1):105-108. doi:10.1006/geno.1995.0019

13. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. *Cancer*. 1998;82(11):2256-2261. https://doi.org/10.1002/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s

14. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. *Urology*. 1998;52(4):637-640. doi:10.1016/s0090-4295(98)00278-7

15. Vlachostergios PJ, Niaz MJ, Sun M, et al. Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. *Front Oncol*. 2021;11:630589. doi:10.3389/fonc.2021.630589

16. Wright GL Jr, Haley C, Beckett ML, et al. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. *Urol Oncol*. 1995;1(1):18-28. doi:10.1016/1078-1439(95)00002-y

17. Zippel C, Ronski SC, Bohnet-Joschko S, Giesel FL, Kopka K. Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov. *Pharmaceuticals (Basel)*. 2020;13(1):12. doi:10.3390/ph13010012

18. Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. *J Nucl Med*. 2015;56(11):1697-1705. doi:10.2967/jnumed.115.161299

19. Banerjee S, Pillai MR, Knapp FF. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. *Chem Rev*. 2015;115(8):2934-2974. doi:10.1021/cr500171e

20. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med*. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322

21. Fizazi K, Herrmann K, Krause BJ, et al. Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*. 2023;24(6):597-610. doi:10.1016/s1470-2045(23)00158-4

22. Herrmann K, Rahbar K, Eiber M, et al. Renal and Multiorgan Safety of (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy. *J Nucl Med*. 2024;65(1):71-78. doi:10.2967/jnumed.123.265448

23. Herrmann K, Krause B, Chi K, et al. Tumour dosimetry across 6 cycles of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: results from the VISION substudy. Presented at: EANM 2024; October 19–23, 2024. Hamburg, Germany. Abstract OP-573. doi:10.1007/s00259-024-06838-z

24. Hofman MS, Emmett L, Sandhu S, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. *Lancet*. 2021;397(10276):797-804. doi:10.1016/s0140-6736(21)00237-3

25. Hofman MS, Emmett L, Sandhu S, et al. Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. *Lancet Oncol*. 2024;25(1):99-107. doi:10.1016/s1470-2045(23)00529-6

26. Oncology Guidelines: Prostate cancer. European Association of Urology. Accessed February 2025. https://uroweb.org/guidelines/prostate-cancer/chapter/treatment

27. Garje R, Rumble RB, Parikh RA. Systemic Therapy Update on (177)Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation. *J Clin Oncol*. 2022;40(31):3664-3666. doi:10.1200/jco.22.01865

28. Morris MJ, Castellano D, Herrmann K, et al. (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. *Lancet*. 2024;404(10459):1227-1239. doi:10.1016/s0140-6736(24)01653-2

29. Azad AA, Dhiantravan N, Emmett L, et al. UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naïve prostate cancer (mHNPC). *J Clin Oncol*. 2021;39(suppl_6):TPS180. doi:10.1200/JCO.2021.39.6_suppl.TPS180

30. Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. *Eur Urol*. 2017;71(2):151-154. doi:10.1016/j.eururo.2016.07.032

31. Evans CP, Higano CS, Keane T, et al. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. *Eur Urol*. 2016;70(4):675-683. doi:10.1016/j.eururo.2016.03.017

32. Emmett L, Subramaniam S, Crumbaker M, et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. *Lancet Oncol*. 2024;25(5):563-571. doi:10.1016/S1470-2045(24)00135-9

33. Emmett L, Subramaniam S, Crumbaker M, et al. Overall survival and quality of life with [(177)Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. *Lancet Oncol*. 2025;26(3):291-299. doi:10.1016/s1470-2045(25)00009-9

34. Sartor O, Jiang DM, Smoragiewicz M, et al. Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH). *Ann Oncol*. 2024;35(suppl_2):S1254-S1255. doi:10.1016/j.annonc.2024.08.2308

35. Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1. *J Nucl Med*. 2018;59(6):878-884. doi:10.2967/jnumed.116.186338

36. Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT. ClinicalTrials.gov. Accessed March 2025. https://clinicaltrials.gov/study/NCT05983198

37. Buteau JP, Martin AJ, Emmett L, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. *Lancet Oncol*. 2022;23(11):1389-1397. doi:10.1016/s1470-2045(22)00605-2

38. Kuo P, Hesterman J, Rahbar K, et al. [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy. *J Clin Oncol*. 2022;40(suppl_16):5002. doi:10.1200/JCO.2022.40.16_suppl.5002

39. Sartor AO, Morris MJ, Messman R, et al. VISION: An international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol*. 2020;38(suppl_6):TPS259. doi:10.1200/JCO.2020.38.6_suppl.TPS259

40. Seifert R, Emmett L, Rowe SP, et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). *Eur Urol*. 2023;83(5):405-412. doi:10.1016/j.eururo.2023.02.002

41. Moradi Tuchayi A, Yadav S, Jiang F, et al. Real-World Experience with (177)Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval. *J Nucl Med*. 2024;65(5):735-739. doi:10.2967/jnumed.123.266842

42. Herrmann K, Gafita A, de Bono JS, et al. Multivariable models of outcomes with [(177)Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial. *EClinicalMedicine*. 2024;77:102862. doi:10.1016/j.eclinm.2024.102862

43. Straub M, Kupferschläger J, Serna Higuita LM, et al. Dual-Time-Point Posttherapy (177)Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome. *J Nucl Med*. 2023;64(9):1431-1438. doi:10.2967/jnumed.122.264770

44. Emmett L, John N, Pathmanandavel S, et al. Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). *Ther Adv Med Oncol*. 2023;15:17588359231156392. doi:10.1177/17588359231156392

45. Yadav S, Lowery B, Tuchayi AM, et al. Impact of Posttreatment SPECT/CT on Patient Management During (177)Lu-PSMA-617 Radiopharmaceutical Therapy. *J Nucl Med*. 2024;65(9):1395-1401. doi:10.2967/jnumed.124.267955

46. Chi KN, Armstrong AJ, Krause BJ, et al. Safety Analyses of the Phase 3 VISION Trial of [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer. *Eur Urol*. 2024;85(4):382-391. doi:10.1016/j.eururo.2023.12.004

47. Gafita A, Fendler WP, Hui W, et al. Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. *Eur Urol*. 2020;78(2):148-154. doi:10.1016/j.eururo.2020.05.004

48. Tagawa ST, Vallabhajosula S, Christos PJ, et al. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer. *Cancer*. 2019;125(15):2561-2569. doi:10.1002/cncr.32072

49. Swiha M, Papa N, Sabahi Z, et al. Development of a Visually Calculated SUV(mean) (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to (177)Lu-PSMA Therapy: Comparison with Quantitative SUV(mean) and Patient Outcomes. *J Nucl Med*. 2024;65(6):904-908. doi:10.2967/jnumed.123.267014

50. Emmett L. Dosing of Radioligand Therapy in Special Situations and/or Toxicity. Presented at: APCCC 2024; 25–27 April 2024. Lugano, Switzerland. Oral presentation 8. https://apccc.org/wp-content/uploads/2023/09/APCCC24_programme_22.09.2023.pdf

51. Steinhelfer L, Lunger L, Cala L, et al. Long-Term Nephrotoxicity of (177)Lu-PSMA Radioligand Therapy. *J Nucl Med*. 2024;65(1):79-84. doi:10.2967/jnumed.123.265986

52. Rosar F, Kochems N, Bartholomä M, et al. Renal Safety of [(177)Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function. *Cancers (Basel)*. 2021;13(12):3095. doi:10.3390/cancers13123095